A sweeping new review shows how disruptions in the gut microbiome may fuel obesity, insulin resistance, and cardiovascular risk, while pointing to diet and other microbiome-focused strategies that could help restore metabolic balance.
Integrative mechanistic framework linking gut dysbiosis to systemic metabolic dysfunction. Arrows indicate the progression of events from exogenous and host-related factors to gut dysbiosis, altered microbial metabolites, barrier dysfunction, and metabolic dysregulation. Upward (↑) and downward (↓) arrows denote increase and decrease, respectively.
A growing body of evidence underscores the role of the gut microbiome in metabolic health. A recent review published in the journal Nutrients identifies gut dysbiosis, or disruption of microbial composition and function, as a major factor associated with metabolic dysfunction through interconnected mechanisms, including oxidative stress, inflammation, and epigenetic changes. Disruption of gut barrier integrity may enable toxin translocation into the bloodstream and liver, amplifying metabolic disturbances. These findings highlight the potential of gut-targeted strategies to improve cardiometabolic outcomes.
Gut microbes play a central role in host metabolism by converting dietary substrates into short-chain fatty acids (SCFAs) that support host and microbial functions while maintaining gastrointestinal homeostasis. However, most research isolates individual aspects of dysbiosis, such as microbial composition, specific mechanisms, or interventions such as fecal microbiota transplantation (FMT), rather than examining their interconnected effects. Disruptions are increasingly linked to metabolic disorders, yet integrated pathways remain unclear. Future studies must adopt multidimensional approaches that connect diet, exercise, genetics, therapeutics, and gut-organ axes to better define holistic models of metabolic health and overall well-being.
In this review, researchers analyzed associations between gut microbial imbalance, oxidative damage, immune pathways, epigenetic processes, and metabolic disease. They drew on 161 peer-reviewed records from Scopus (2000 to January 2025), with emphasis on more recent literature and inclusion of both experimental and observational studies, as well as mechanistic findings from preclinical models.
Link between gut dysbiosis and systemic metabolic dysfunction
Gut dysbiosis contributes to cardiometabolic disease through a network of metabolic, inflammatory, and barrier-related mechanisms. It is characterized by reduced microbial alpha diversity and alterations in the Firmicutes/Bacteroidetes ratio, although this ratio alone is an oversimplified marker and may vary across populations and study methods. There is a loss of SCFA-producing bacteria such as Roseburia spp. and Faecalibacterium prausnitzii, and expansion of pathobionts including Escherichia coli and Enterobacteriaceae. The review presents these taxa as context-dependent examples rather than universal biomarkers of dysbiosis.
Reduced SCFA availability, particularly butyrate, weakens epithelial tight junctions, undermines gut barrier function, and limits anti-inflammatory signaling. In parallel, increased intestinal permeability promotes lipopolysaccharide (LPS) translocation into circulation, activating Toll-like receptor (TLR)-mediated pathways and triggering pro-inflammatory cytokine production. These include tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and interleukin-6 (IL-6), which collectively drive chronic low-grade inflammation and insulin resistance.
Microbial metabolites amplify metabolic risk. Dysbiotic communities increase trimethylamine (TMA) production, which is converted in the liver to trimethylamine N-oxide (TMAO), a pro-atherogenic molecule that promotes endothelial dysfunction and leukocyte activation. Altered microbiota also enhance branched-chain amino acid synthesis. Species such as Prevotella copri and Bacteroides vulgatus are linked to insulin resistance. In obesity and type 2 diabetes, studies report reduced diversity, depletion of butyrate producers, and enrichment of opportunistic taxa including Clostridium citroniae.
These compositional and functional shifts modify bile acid pathways, gut hormone secretion, including glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), and immune balance. The result is a self-reinforcing cycle of inflammation, metabolic dysregulation, and microbial imbalance that may help sustain obesity, insulin resistance, and cardiovascular disease. The review also notes that these relationships are often bidirectional, meaning dysbiosis may act as both a contributor to and a consequence of metabolic dysfunction.
Conceptual overview of gut microbiome homeostasis and progression toward dysbiosis-associated metabolic dysfunction. Icons and schematic elements used in this illustration were created using AI-assisted graphic tools and were further modified and assembled by the authors.
Microbiome-targeted interventions to improve metabolic health
Targeting the gut microbiome offers a practical route to improve cardiometabolic outcomes. Dietary strategies remain central. High-fiber diets, rich in fruits, vegetables, legumes, and whole grains, promote SCFA-producing microbes, enhance epithelial barrier integrity, and improve insulin sensitivity. In contrast, diets high in refined carbohydrates and saturated fats suppress tight junction (TJ) protein expression, increase pro-inflammatory cytokines, and alter bile acid signaling, collectively impairing gut barrier function. Probiotics and prebiotics further support microbial balance by enhancing SCFA production, limiting pathogen overgrowth, and modulating immune responses. Emerging next-generation probiotics (NGP) and postbiotics may offer more targeted metabolic benefits.
Lifestyle factors also shape microbial composition and function. Regular physical activity increases microbial diversity and butyrate production, while stress-reduction practices, such as mindfulness and meditation, help modulate gut-brain signaling and limit inflammation. Sleep quality and circadian alignment further maintain microbial rhythmicity and metabolic balance. Conversely, irregular eating patterns, chronic stress, alcohol use, and medications such as antibiotics and proton-pump inhibitors can drive dysbiosis and should be carefully managed.
FMT represents a more direct intervention. Clinical and experimental studies suggest that FMT can shift microbial composition, improve insulin sensitivity, and modestly alter fat distribution, particularly when combined with dietary interventions. Still, the review presents FMT as a promising approach rather than a firmly established therapy for metabolic disease.
Importantly, host factors such as genetics and aging also influence microbiome structure and metabolic responses, shaping individual variability in treatment outcomes. Epigenetic mechanisms, particularly deoxyribonucleic acid (DNA) methylation, further modulate this relationship, as microbial metabolites such as folate, S-adenosylmethionine, and SCFAs can alter methylation patterns and gene expression. These changes influence metabolic and inflammatory pathways and contribute to disease susceptibility. The review also discusses exploratory possibilities such as longer-term epigenetic imprinting, although these remain less established.
Overall, the gut microbiota is a key regulator of metabolic and immune homeostasis, with dysbiosis linked to oxidative stress, inflammation, and epigenetic changes associated with cardiometabolic disease. Because the evidence spans heterogeneous human, animal, and mechanistic studies, further work is needed to clarify causal pathways. Identifying early microbial markers and refining interventions will be essential for targeted therapies. At the population level, policies promoting fiber-rich diets and limiting ultra-processed foods are critical, while at the individual level, balanced nutrition, physical activity, stress management, and microbiome-focused strategies may improve long-term health outcomes.
Palmatine improved fatty liver markers in a preclinical type 2 diabetes study